News
11-23-2010, 11:41 PM
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company's Phase 2 trial of PV-10 for metastatic melanoma, as well as more than 30 new patients.
More... (http://www.news-medical.net/news/20101124/Provectus-reports-progress-in-PV-10-program-for-metastatic-melanoma.aspx)
More... (http://www.news-medical.net/news/20101124/Provectus-reports-progress-in-PV-10-program-for-metastatic-melanoma.aspx)